SBE APTAMERS FOR TREATING IL-17a RELATED DISEASES AND CONDITIONS

Abstract

Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

We claim: 
     
         1 . A method of treating an IL-17a related disease or condition comprising:
 treating a subject with an IL-17a related disorder or condition with a composition, wherein said composition comprises a first nucleic acid sequence, wherein said first nucleic acid sequence comprises an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.   
     
     
         2 . The method of  claim 1 , wherein at least a portion of said SBE nucleic acid sequence is from a gene selected from CXCL1, GM-CSF, and TNF. 
     
     
         3 . The method of  claim 1 , wherein said SBE nucleic acid sequence comprises a sequence shown in SEQ ID NOs:1-2, 49-61, 88-94, and 99-129. 
     
     
         4 . The method of  claim 1 , wherein said SBE nucleic acid sequence comprises RNA bases. 
     
     
         5 . The method of  claim 1 , wherein said SBE nucleic acid sequence comprises DNA bases. 
     
     
         6 . The method of  claim 1 , wherein said treating reduces or eliminates at least one symptom related to said IL-17a related disease or condition. 
     
     
         7 . The method of  claim 1 , wherein said IL-17a related disease is selected from the group consisting of: psoriasis, chronic plaque, asthma, an autoimmune disease, an inflammatory condition, rheumatoid arthritis, and multiple sclerosis. 
     
     
         8 . The method of  claim 1 , wherein said SBE nucleic acid sequence comprises, consist of, or consists essentially of: nucleotides 810-857 of said CXCL1 gene, ii) nucleotides 830-856 of said CXCL1 gene, or iii) nucleotides 800-835 of said CXCL1 gene. 
     
     
         9 . The method of  claim 1 , wherein said subject is human. 
     
     
         10 . The method of  claim 1 , wherein said SBE nucleic acid sequence is from a human gene. 
     
     
         11 . The method of  claim 1 , wherein said ACT1 protein is human ACT1 protein. 
     
     
         12 . The method of  claim 1 , wherein said first nucleic acid sequence is between 12 and 70 nucleotides in length. 
     
     
         13 . A composition comprising a first nucleic acid sequence, wherein said first nucleic acid sequence comprises an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein, and wherein said first nucleic acid sequence comprises modified bases to improve stability in vivo. 
     
     
         14 . The composition of  claim 13 , wherein said SBE nucleic acid sequence is from a gene selected from CXCL1, GM-CSF, and TNF. 
     
     
         15 . The composition of  claim 13 , wherein said first nucleic acid sequence is no longer than 70 bases and comprises at least: i) nucleotides 830-856 of said CXCL1 gene, or ii) nucleotides 810-857 of said CXCL1 gene. 
     
     
         16 . The composition of  claim 13 , wherein said first nucleic acid sequence is composed of RNA bases. 
     
     
         17 . The composition of  claim 13 , wherein said first nucleic acid is present in said composition at a level that is therapeutic when administered to a subject with an IL-17a related disease or condition. 
     
     
         18 . A composition comprising a first nucleic acid sequence, wherein said first nucleic acid sequence comprises an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein, and wherein said SBE nucleic acid sequence comprises a sequence shown in SEQ ID NO:1, 2, or 103, but which is not naturally occurring. 
     
     
         19 . The composition of  claim 18 , wherein said first nucleic acid sequence comprises modified bases to improve stability in vivo. 
     
     
         20 . The composition of  claim 18 , wherein said first nucleic acid sequence is present in said composition at a level that is therapeutic when administered to a subject with an IL-17a related disease or condition.